Comment on: Singer et al. Adiponectin and All-Cause Mortality in Elderly People With Type 2 Diabetes. Diabetes Care 2012;35:1858–1863

Liu, Jing; Tavintharan, S.; Sum, Chee Fang; Lim, Su Chi

doi:10.2337/dc12-1814

Cited by 2 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Full vaccination showed numerically higher VE in the 60–79 years population (74.9%) than in the 35–59 years (5.8) or the >80 years group (63.3%). As for the booster shot, the VE was highest in the 35–59 years group (96.3%), as compared with the 60–79 years (90.3%) or the >80 years (77.8%) group 42. Our own data are not directly comparable with Liu et al , but they indicate a somewhat lower VE in the 65–100 years group as compared with the cohort aged 45–64 years.…”

Section: Discussioncontrasting

confidence: 79%

See 1 more Smart Citation

Effectiveness of SARS-CoV-2 primary vaccines and boosters in patients with type 2 diabetes mellitus in Hungary (HUN-VE 4 Study)

Molnár,

Vokó,

Sütő

et al. 2024

BMJ Open Diab Res Care

View full text Add to dashboard Cite

IntroductionType 2 diabetes mellitus is a risk factor for severe COVID-19 infection and is associated with increased risk of complications. The present study aimed to investigate effectiveness and persistence of different COVID vaccines in persons with or without diabetes during the Delta wave in Hungary.Research design and methodsData sources were the national COVID-19 registry data from the National Public Health Center and the National Health Insurance Fund on the total Hungarian population. The adjusted incidence rate ratios and corresponding 95% CIs were derived from a mixed-effect negative binomial regression model.ResultsA population of 672 240 cases with type 2 diabetes and a control group of 2 974 102 non-diabetic persons free from chronic diseases participated. Unvaccinated elderly persons with diabetes had 2.68 (95% CI 2.47 to 2.91) times higher COVID-19-related mortality rate as the ‘healthy’ controls. Primary immunization effectively equalized the risk of COVID-19 mortality between the two groups. Vaccine effectiveness declined over time, but the booster restored the effectiveness against mortality to over 90%. The adjusted vaccine effectiveness of the primary Pfizer-BioNTech against infection in the 14–120 days of postvaccination period was 71.6 (95% CI 66.3 to 76.1)% in patients aged 65–100 years with type 2 diabetes and 64.52 (95% CI 59.2 to 69.2)% in the controls. Overall, the effectiveness tended to be higher in individuals with diabetes than in controls. The booster vaccines could restore vaccine effectiveness to over 80% concerning risk of infection (eg, patients with diabetes aged 65–100 years: 89.1 (88.1–89.9)% with Pfizer-on-Pfizer, controls 65–100 years old: 86.9 (85.8–88.0)% with Pfizer-on-Pfizer, or patients with diabetes aged 65–100 years: 88.3 (87.2–89.2)% with Pfizer-on-Sinopharm, controls 65–100 years old: 87.8 (86.8–88.7)% with Pfizer-on-Sinopharm).ConclusionsOur data suggest that people with type 2 diabetes may have even higher health gain when getting vaccinated as compared with non-diabetic persons, eliminating the marked, COVID-19-related excess risk of this population. Boosters could restore protection.

show abstract

Section: Discussioncontrasting

confidence: 79%

“…Liu et al 42 presented regional data for a period after December 2022 (ie, presumably during the Omicron wave) on patients with T2DM. They obtained VE for individuals with T2DM only, as there was no non-diabetic control group involved.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of SARS-CoV-2 primary vaccines and boosters in patients with type 2 diabetes mellitus in Hungary (HUN-VE 4 Study)

Molnár,

Vokó,

Sütő

et al. 2024

BMJ Open Diab Res Care

View full text Add to dashboard Cite

show abstract

“…Moreover, such patients have been associated with an increased risk for opportunistic infections [6]. Limited research has been conducted on the association between COVID-19 vaccination status and outcomes such as supplemental oxygen requirement, intensive care unit (ICU) admissions, and mortality, specifi cally in patient cohorts with uncomplicated type 2 diabetes mellitus (DM) as the only chronic condition [7]. Therefore, our study aimed to investigate the potential associations between these parameters.…”

mentioning

confidence: 99%

The Impact of COVID-19 Vaccination on Bulgarian Patients with Uncomplicated Type 2 Diabetes Mellitus as the Only Chronic Condition

Valkov,

Dimitrov

2023

Acta Medica Bulgarica

View full text Add to dashboard Cite

Objective: This retrospective study aimed to investigate the impact of COVID-19 vaccination on Bulgarian patient cohorts with uncomplicated diabetes mellitus type 2 as the only documented chronic comorbidity. We conducted a comparison of fully vaccinated and non-vaccinated populations, considering gender, age groups and vaccine type, across ambulatory, hospital, and ICU settings. Design: Between March 2020 and June 2022, a comprehensive retrospective analysis was conducted on a national level, utilizing data from the Ministry of Health of the Republic of Bulgaria database obtained after a formal written request. The study included a total of 1,126,946 confirmed COVID-19 patients. Results: Among the 1,126,946 confirmed COVID-19 patients, 3,792 individuals (0.33% of the total confirmed cases) had diabetes mellitus as a single chronic condition. Among the 247,441 hospitalized COVID-19 cases, 1,382 patients (0.56% of the total) had type 2 diabetes mellitus. Notably, the majority of patients requiring hospitalization due to supplemental oxygen requirement were unvaccinated women aged between 60 and 69, accounting for 240 patients. The highest mortality rates were observed in both unvaccinated men and women aged between 70 and 79, with 88 patients in each group. Statistical analysis revealed significant findings in favor of reduced rates of ambulatory care [OR = 0.76 (95% CI 0.6471 to 0.8891); p = 0.0006], intensive care admission [OR = 0.38 (95% CI 0.2698 to 0.5282); p < 0.0001], in-hospital mortality [OR = 0.18 (95% CI 0.0864 to 0.3604); p < 0.0001], and ICU-related mortality [OR = 0.17 (95% CI 0.0893 to 0.3436); p < 0.0001]. The vaccinated cohorts who received BNT162b2 demonstrated the lowest observed death rates, with 9 deaths out of 485 individuals (1.8%) across all age groups. Conclusion: In conclusion, this retrospective analysis indicates reduced mortality in patients with uncomplicated type II diabetes mellitus who received vaccination against SARS-CoV-2. Vaccinated individuals also showed significant reduction in ICU admissions.

show abstract

Comment on: Singer et al. Adiponectin and All-Cause Mortality in Elderly People With Type 2 Diabetes. Diabetes Care 2012;35:1858–1863

Cited by 2 publications

References 4 publications

Effectiveness of SARS-CoV-2 primary vaccines and boosters in patients with type 2 diabetes mellitus in Hungary (HUN-VE 4 Study)

Effectiveness of SARS-CoV-2 primary vaccines and boosters in patients with type 2 diabetes mellitus in Hungary (HUN-VE 4 Study)

The Impact of COVID-19 Vaccination on Bulgarian Patients with Uncomplicated Type 2 Diabetes Mellitus as the Only Chronic Condition

Contact Info

Product

Resources

About